Clinical Trials Logo

Overweight clinical trials

View clinical trials related to Overweight.

Filter by:

NCT ID: NCT00752726 Completed - Obesity Clinical Trials

Effect of Orlistat in Body Composition

Start date: September 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if a 24 week weight loss program with orlistat 60 mg will produce greater changes in body composition compared to placebo.

NCT ID: NCT00747942 Completed - Overweight Clinical Trials

Support for Increased Physical Activity (Stöd Till Aktivare Motion)

STAM
Start date: October 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to improve and analyze the level of physical activity in immigrant women from the Middle East and Latin America living in Sweden. The investigators will also investigate if glucose, insulin, and lipid metabolism; stress-related hormone production; and subclinical inflammatory activity are affected by the intervention. The follow-up period is 2 years.

NCT ID: NCT00746629 Completed - Clinical trials for Overweight and Obesity

Familial Overweight: Comparing Use of Strategies

FOCUS
Start date: May 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the efficacy of two different approaches (prescribed & self-directed) to the treatment of childhood obesity and their relative impact on child weight status, physical activity, and diet.

NCT ID: NCT00746083 Completed - Overweight Clinical Trials

Challenge!, a Health Promotion/ Obesity Prevention Program for Teens

Start date: April 2001
Phase: N/A
Study type: Interventional

The purpose of Challenge! is to determine if adolescents enrolled in a health promotion/ obesity prevention program will have a healthier BMI-for-age z-score and body composition (body fat %), will consume a healthier diet, and engage in higher levels of physical activity compared to those that did not receive the intervention over time.

NCT ID: NCT00741923 Completed - Obesity Clinical Trials

Effect of Consuming Beans for One Month on Blood Lipids, Satiety, Intake Regulation and Body Weight

Start date: November 2007
Phase: N/A
Study type: Interventional

This project investigates the effect of regular consumption of commercially available processed white beans (5 cups per week) on food intake, body weight, blood pressure, satiety hormones and glycemic response over a 4-week period. We have chosen to provide participants with canned white beans, the most accessible and frequently consumed bean in North America. They are inexpensive, a good source of high quality nutrients and ready to eat. Based upon published literature and short-term studies conducted in our laboratory, we hypothesize that regular consumption of commercially available canned beans will increase satiety and improve the control of food intake, body weight, blood glucose and blood lipids.

NCT ID: NCT00739479 Completed - Metabolic Syndrome Clinical Trials

CCRC: Effects of Partially Hydrolyzed Whey Peptides (PHWP) On Weight Loss In Individuals With The Metabolic Syndrome (METS)

Start date: August 2008
Phase: N/A
Study type: Interventional

The aim of this study is to compare the effects of two different protein supplements (partially hydrolyzed whey protein, PHWP vs. partially hydrolyzed gelatin, PHG) on weight loss in obse individuals with metabolic syndrome (METS). These two supplements will contain equal amounts of protein but differ considerably in their amino acid contents. Whey protein is rich in essential amino acids whereas gelatin is rich in proline. In obese individuals with METS, the hypotheses are: - PHWP will augment fat-mass loss and increase lean-mass to fat-mass ration more than PHG. - PHWP will improve insulin action more than PHG. - PHWP will decrease cardiovascular disease risk more than PHG.

NCT ID: NCT00731094 Completed - Obesity Clinical Trials

The VA-STRIDE Study

Start date: June 2010
Phase: N/A
Study type: Interventional

The purpose of the study was to examine the effectiveness of an expert-system, print-based physical activity (PA) intervention delivered to Veterans receiving primary care at the VA Pittsburgh Healthcare System (VAPHS).

NCT ID: NCT00715130 Completed - Obesity Clinical Trials

Move and Moderate in Balance

MOVE'M
Start date: September 2005
Phase: N/A
Study type: Interventional

H1: The increase in body mass index between baseline and two year follow-up among intervention worksites will be lower than that among control worksites, such that the differential change will be negative on average.

NCT ID: NCT00711477 Completed - Obesity Clinical Trials

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

Start date: September 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the effect of naltrexone SR/bupropion SR (NB) on brain function in response to food cues using functional magnetic resonance imaging in overweight or obese subjects.

NCT ID: NCT00710814 Completed - Overweight Clinical Trials

Trial of Leptin Administration After Roux-en-Y Gastric Bypass

Start date: April 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This is a pilot and feasibility study to examine a novel intervention using leptin in weight-reduced individuals who have undergone bariatric surgery but still remain obese. Leptin, a peptide hormone secreted from adipose tissue, is a regulator of food intake and energy expenditure. Administration of leptin resulted in profound weight reduction in the few reported cases of obese individuals with genetic leptin deficiency. However, most obese people have increased leptin levels. Such individuals are said to be in a "leptin-resistant" state, whereby administration of physiological concentrations of leptin are ineffective at producing significant weight reduction. Roux-en-Y gastric bypass surgery (RYGBP) is more effective than diet alone in producing long-term reduction of body weight. Yet even after surgery there is a plateau in weight loss though the individual may still be obese and have or be at risk for obesity related morbidities. The investigators have shown that plasma leptin levels are significantly lower in women after RYGBP compared with BMI-matched controls. This state of relative hypoleptinemia or leptin insufficiency suggests that post-RYGBP individuals may be in a "leptin-sensitive" state and, thus, would undergo further weight loss when administered doses of leptin that would not normally result in significant weight reduction. This study will examine the effects of leptin administered by self-injection twice per day on body weight and endocrine function. All individuals will received leptin and placebo and different times during the 34 week study period.